SABS
SAB Biotherapeutics Inc
3.10$
+4.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | – | – | – | – | – | – | – | |
| 77.8% | 309.6% | 210.1% | 388.4% | – | 685.0% | – | – | – | – | – | – | – | |
| 22.3% | -209.5% | -110.1% | -288.4% | – | -585.0% | – | – | – | – | – | – | – | |
| 317.3% | 1,408.8% | 860.1% | 2,584.3% | – | 6,652.2% | – | – | – | – | – | – | – | |
| 202.9% | 4,878.8% | 443.5% | 1,384.4% | – | 2,328.7% | – | – | – | – | – | – | – | |
| 442.4% | 5,978.3% | 1,095.8% | 3,588.6% | – | 8,141.2% | – | – | – | – | – | – | – | |
| -420.1% | -6,188.0% | -1,205.9% | -3,877.0% | – | -8,726.3% | – | – | – | – | – | – | – | |
| 5.5% | 25.5% | 8.1% | 35.4% | – | 61.8% | – | – | – | – | – | – | – | |
| -402.7% | -7,493.8% | -532.1% | -2,787.7% | – | -9,934.5% | – | – | – | – | – | – | – | |
| 13.2% | 0.0% | -1,416.0% | – | – | 11,661.4% | – | – | – | – | – | – | – | |
| -402.7% | -7,493.8% | -532.1% | -2,787.7% | – | -9,934.5% | – | – | – | – | – | – | – | |
| -319.4% | -7,158.4% | -313.9% | -2,363.9% | – | -9,187.7% | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.